MRPL22

Across TCGA pan-cancer cohorts, MRPL22 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MRPL22 data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MRPL22 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MRPL22 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where MRPL22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.381	0.809	.001	27	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	6	view →
LSCC	OS	Tertile	II,III,IV	0.951	0.659	.025	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MRPL22–CCRCC (DFS)

Open the CCRCC breakdown →